Entheon Biomedical (XCNQ:ENBI) EV-to-EBIT : -3.84 (As of May. 16, 2024)

View and export this data going back to 2018. Start your Free Trial

What is Entheon Biomedical EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Entheon Biomedical's Enterprise Value is C$1.08 Mil. Entheon Biomedical's EBIT for the trailing twelve months (TTM) ended in Feb. 2024 was C$-0.28 Mil. Therefore, Entheon Biomedical's EV-to-EBIT for today is -3.84.

The historical rank and industry rank for Entheon Biomedical's EV-to-EBIT or its related term are showing as below:

XCNQ:ENBI' s EV-to-EBIT Range Over the Past 10 Years
Min: -4.44 Med: -0.79 Max: 0.16
Current: -3.83

During the past 7 years, the highest EV-to-EBIT of Entheon Biomedical was 0.16. The lowest was -4.44. And the median was -0.79.

XCNQ:ENBI's EV-to-EBIT is ranked worse than
100% of 429 companies
in the Biotechnology industry
Industry Median: 9.84 vs XCNQ:ENBI: -3.83

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Entheon Biomedical's Enterprise Value for the quarter that ended in Feb. 2024 was C$0.34 Mil. Entheon Biomedical's EBIT for the trailing twelve months (TTM) ended in Feb. 2024 was C$-0.28 Mil. Entheon Biomedical's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Feb. 2024 was -82.43%.

Entheon Biomedical EV-to-EBIT Historical Data

The historical data trend for Entheon Biomedical's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Entheon Biomedical EV-to-EBIT Chart

Entheon Biomedical Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Nov21

Nov22

Nov23

EV-to-EBIT

Get a 7-Day Free Trial

-4.52

-2.77

-3.63

-0.30

-0.78

Entheon Biomedical Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
EV-to-EBIT	Get a 7-Day Free Trial															-0.59	-1.52	-2.34	-0.78	-1.21

Competitive Comparison of Entheon Biomedical's EV-to-EBIT

For the Biotechnology subindustry, Entheon Biomedical's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Entheon Biomedical's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Entheon Biomedical's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Entheon Biomedical's EV-to-EBIT falls into.

Entheon Biomedical EV-to-EBIT Calculation

Entheon Biomedical's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	1.079	/	-0.281
	=	-3.84

Entheon Biomedical's current Enterprise Value is C$1.08 Mil.
Entheon Biomedical's EBIT for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.28 Mil.

Entheon Biomedical (XCNQ:ENBI) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Entheon Biomedical's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Feb. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Feb. 2024 )	=	EBIT	/	Enterprise Value (Q: Feb. 2024 )
	=	-0.281	/	0.340893
	=	-82.43 %

Entheon Biomedical's Enterprise Value for the quarter that ended in Feb. 2024 was C$0.34 Mil.
Entheon Biomedical's EBIT for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.28 Mil.

Entheon Biomedical EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Entheon Biomedical's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Entheon Biomedical (XCNQ:ENBI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Entheon Biomedical Corp (XCNQ:ENBI) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

ENTBF:USA 1XU1:Germany

Address

999 West Broadway Street, Suite 720, Vancouver, BC, CAN, V5Z 1K5

Website

https://www.entheonbiomedical.com

Entheon Biomedical Corp is a biotechnology research and development company committed to developing and commercializing a portfolio of safe and effective Dimethyltryptamine based psychedelic therapeutic products (DMT Products) for the purposes of treating addiction and substance use disorders. Entheon intends to generate revenue through the sale of its DMT Products to physicians, clinics, and licensed psychiatrists in the United States, certain countries in the European Union, and throughout Canada.

Entheon Biomedical (XCNQ:ENBI) Headlines

No Headlines